United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - efavirenz - tablet - 600mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. coadminstration of atripla with voriconazole is contraindicated. efavirenz, a component of atripla, significantly decreases voriconazole plasma concentrations, and coadministration may decrease the therapeutic effectiveness of voriconazole. also, voriconazole significantly increases efavirenz plasma concentrations, which may increase the risk of efavirenz-associated side effects. because atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered [see clinical pharmacology (12.3) tables 4 and 5]. pregnancy category d [see warnings and precautions (5.9)] antiret

United States - English - NLM (National Library of Medicine)

doh central pharmacy - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] the centers for disease control and prevention recommend that hiv-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of hiv-1. studies in rats have demonstrated that both efavirenz and tenofovir are secreted in milk. it is n

Canada - English - Health Canada

mylan pharmaceuticals ulc - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

teva canada limited - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

auro pharma inc - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

jamp pharma corporation - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] antiretroviral pregnancy registry: to monitor fetal outcomes of pregnant women, an antiretroviral pregnancy registry has been established. physicians are encouraged to register patients who become pregnant by cal

United States - English - NLM (National Library of Medicine)

gilead sciences, llc - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)] . - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at (800) 258-4263. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were e

United States - English - NLM (National Library of Medicine)

gilead sciences, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla™ is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)]. - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients who become pregnant on the worldwide web at www.apregistry.com/. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-conta